The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT)

Takeda, Atsuya; Yokosuka, Noriko; Ohashi, Toshio; Kunieda, Etsuo; Fujii, Hirofumi; Aoki, Yousuke; Sanuki, Naoko; Koike, Naoyoshi; Ozawa, Yukihiko

doi:10.1016/j.radonc.2011.08.008

Cited by 93 publications

(67 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Burdick et al (22) analyzed pretreatment SUV max in 72 patients with inoperable T1-2N0M0 NSCLC treated with SBRT and concluded that pretreatment SUV max did not predict for local control, mediastinal failure, distant metastases or OS. In Japan, Takeda et al (23) revealed that a high SUV max of the primary tumor was associated with a significantly worse local control rate in 95 patients with NSCLC treated with SBRT. It was concluded that NSCLC tumors with a high SUV max may require dose escalation to improve local control, but patient outcomes were not studied.…”

Section: Discussionmentioning

confidence: 99%

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study (University Hospital Medical Information Network study no. UMIN000003797) aimed to evaluate whether the maximum standardized uptake value (SUV max ) of pretreatment 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is prognostic factor for stage I non-small cell lung cancer (NSCLC) treated with carbon ion radiotherapy (C-ion RT). Patients treated between June 2010 and June 2013 at Gunma University Heavy Ion Medical Center (Maebashi, Japan) on a prospective protocol were included in the present study. Patients with T1a-b and T2a NSCLC were treated with C-ion RT at a dose of 52.8 Gy [relative biological effectiveness (RBE)] and 60.0 Gy (RBE), respectively, in four fractions. Prior to treatment, all patients underwent FDG-PET, in which the SUV max of primary tumors was evaluated. Local control, progression-free survival (PFS), and overall survival (OS) were calculated. A total of 45 patients were analyzed and the median follow-up period was 28.9 months. The 2-year local control, PFS and OS rates for all patients were 93, 78 and 89%, respectively. The mean SUV max of primary tumors was 5.5, and patients were divided into higher (≥5.5) and lower (<5.5) SUV max groups. The 2-year PFS rates were 61 and 89% for the higher and lower SUV max groups, respectively (P=0.01), and the 2-year OS rates for the higher and lower SUV max groups were 76 and 96%, respectively (P=0.01). The higher SUV max group exhibited a significantly worse PFS and OS compared with the lower SUV max group; however, the SUV max was not associated with the local control rate. In total, 2 patients (4%) experienced grade 2 or 3 radiation pneumonitis, with their symptoms improved through conservative treatment. No patients experienced any grade 4 or 5 toxicities. The results of the present study indicate that pretreatment SUV max is a prognostic indicator for outcomes in patients with stage I NSCLC treated with C-ion RT.

show abstract

Section: Discussionmentioning

confidence: 99%

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Standardized uptake value (SUV) is a semiquantitative index that characterizes [ 18 F]FDG uptake approximating the glucose metabolic rate. A close correlation between SUV and prognosis in lung cancer patients after SABR has been suggested [35,36]. Clarke et al [35] found that pre-SABR SUVmax on [ 18 F]FDG-PET scan has strong correlation to distant failure in medically inoperable early-stage NSCLC patients.…”

Section: Discussionmentioning

confidence: 95%

“…Clarke et al [35] found that pre-SABR SUVmax on [ 18 F]FDG-PET scan has strong correlation to distant failure in medically inoperable early-stage NSCLC patients. Taketa et al [36] concluded that the higher SUVmax > 6 was a strong predictor of local recurrence for NSCLC after SABR. In our study, higher SUVmax of more than 6 was found as a strong predictor for LNMFS, PFS, and OS, but not for LCR.…”

Section: Discussionmentioning

confidence: 99%

Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas

Lee

Moon²,

Cho

et al. 2016

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…9 Acuteness of FDG-based criteria is shown particularly in the evaluation of patients with Non-Small Cell Lung Cancer treated with SBRT. [10][11][12][13][14] We bring together in this work articles of English language literature estimating the response of hepatic lesions treated by SBRT.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of response after SBRT for liver tumors

Tétreau

Llacer

Riou

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Use of RECIST criteria is also inadequate in the evaluation of response after SBRT for hepatic metastases. Response of liver metastases to SBRT is better assessed with a combination of size and enhancement pattern. The occurrence of a lobulated enhancement during follow up is efficient to predict local progression in a specific, reproducible, and sensitive way. Patients with FDG-avid hepatic metastases are also better evaluated with PET-CT and functional criteria than routine imaging and metric evaluation alone.

show abstract

The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT)

Cited by 93 publications

References 40 publications

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas

Evaluation of response after SBRT for liver tumors

Contact Info

Product

Resources

About